Status:
NOT_YET_RECRUITING
Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Danish Child Cancer Foundation
Danish Cancer Society
Conditions:
Stem Cell Transplant
Late Effect
Eligibility:
All Genders
7+ years
Brief Summary
Today the overall survival of childhood cancers has increased to above 85%. This increase is partially caused by treatment with bone marrow transplantation. A bone marrow transplantation is an efficie...
Eligibility Criteria
Inclusion
- =/\> 7 years of age
- treatment with HSCT in Denmark since 2010
- treatment with HSCT was before the age of 18 years
- ability to speak and understand Danish.
Exclusion
- diagnosed with infantile autism before their HSCT
- Downs Syndrome
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT07140445
Start Date
September 1 2025
End Date
March 1 2027
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Capital Region, Denmark, 2100